Brief: AB Science Updates On Phase 2B/3 Study Evaluating Masitinib In Alzheimer’S Disease

AB Science SA

18/12/2020 07:53

Dec 18 (Reuters) - AB Science SA  ABS.PA :
    * AB SCIENCE COMMUNICATES THE RESULTS FROM PHASE 2B/3 STUDY EVALUATING
MASITINIB
IN ALZHEIMER’S DISEASE
    * STUDY MET ITS PRIMARY ANALYSIS, DEMONSTRATING A STATISTICALLY SIGNIFICANT
REDUCTION IN COGNITIVE IMPAIRMENT BASED ON ADAS-COG (P=0.0003)
    * TREATMENT-EFFECT WITH RESPECT TO CONTROL ARM (I.E., BETWEEN GROUP
DIFFERENCE OF
LEAST SQUARES MEAN (LS MEAN) AND ASSOCIATED STANDARD ERROR (SE) IN ADAS-COG WAS
-2.15 (0.59
    * ADAS-COG SENSITIVITY ANALYSIS BASED ON JUMP TO REFERENCE IMPUTATION METHOD
REMAINED POSITIVE (P=0.0016), DEMONSTRATING A ROBUST TREATMENT STATISTICAL
EFFECT
    * STUDY DEMONSTRATED A STATISTICALLY SIGNIFICANT IMPROVEMENT ON DAILY
ACTIVITY
BASED ON ADCS-ADL (P=0.0381). DIFFERENCE OF LS MEAN (SE) IN ADCS-ADL WAS 1.82
(0.87)
    * ADCS-ADL SENSITIVITY ANALYSIS BASED ON JUMP TO REFERENCE IMPUTATION METHOD
SHOWED A NUMERICAL ADVANTAGE CLOSE TO STATISTICAL SIGNIFICANCE (P=0.051) IN
FAVOR OF MASITINIB
    * A NEW PATENT WAS FILED BASED ON RESULTS FROM STUDY AB09004, WHICH WOULD
PERMIT
AB SCIENCE TO RETAIN EXCLUSIVE RIGHTS ON USE OF MASITINIB IN ALZHEIMER'S DISEASE
UNTIL 2041

Source text for Eikon:  ID:nGNX8qzhJ6 
Further company coverage:  ABS.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))